Interview: GSK India's Playbook For Vaccines Dominance

Deft pricing and effective physician engagement appear to have helped shape GSK's sustained dominance in the Indian self-pay vaccines market. GSK Pharmaceuticals India managing director, Annaswamy Vaidheesh, takes Scrip through some of the strategies at play including the sharp recalibration in the price of Synflorix and how the British multinational is harnessing digital technology to stay "close" to its customers.

Leadership

GlaxoSmithKline Pharmaceuticals Ltd. has been a leader in the self-pay vaccines segment in India for over a decade and the firm's top management indicates that timing the launch right, a "dedicated and trained" field force and "good insight" about pricing have been vital in staying ahead of competition.

"It's very easy to launch a new product which has got great value to add and skim it at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

More from Scrip

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By 

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

Executives On The Move: Four New CEOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.